Tourmaline Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2002-01-01
- Employees
- 44
- Market Cap
- $428.2M
- Website
- http://www.tourmalinebio.com
- Introduction
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
Phase 2
Active, not recruiting
- Conditions
- Hs-CRPChronic Renal DiseasesHigh Sensitivity C-Reactive ProteinChronic Kidney DiseasesChronic Kidney InsufficiencyC-Reactive ProteinKidney Insufficiency, ChronichsCRPChronic Renal Insufficiency
- Interventions
- Drug: TOUR006 - 15 MGDrug: TOUR006 - 25 MGOther: PlaceboDrug: TOUR006 - 50 MG
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Tourmaline Bio, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT06362759
- Locations
- 🇺🇸
Site - 0124, Birmingham, Alabama, United States
🇺🇸Site - 0101, Birmingham, Alabama, United States
🇺🇸Site - 0135, Huntsville, Alabama, United States
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
Phase 2
Recruiting
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: TOUR006 - 20 MGOther: PlaceboDrug: TOUR006 - 50 MG
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Tourmaline Bio, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT06088979
- Locations
- 🇺🇸
Mayo Clinic Site - 0102, Rochester, Minnesota, United States
🇺🇸Hackensack University Medical Center Site - 0105, Hackensack, New Jersey, United States
🇺🇸Catalina Eye Care Site - 0121, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath